Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study

Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study

Submitted by admin on December 1, 2022 - 7:10pm
Source: 
BioSpace
News Tags: 
Eli Lilly
donanemab
clinical trials
Aduhelm
Biogen
Alzheimer's disease
Headline: 
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
snippet: 

Eli Lilly’s investigational antibody donanemab met all of its primary and secondary endpoints in the Phase III TRAILBLAZER-ALZ 4 study, the company announced Wednesday.

Do Not Allow Advertisers to Use My Personal information